Johnson & Johnson (JNJ)

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a firesid...

A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend ...

Johnson & Johnson (JNJ -0.47%) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy.

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to ...

Johnson & Johnson (JNJ -0.47%) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, i...

Johnson & Johnson (JNJ -0.47%) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.

The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal health agencies' payments of medical costs for patients who allege that the ...

On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 1...

Two Sigma Investments founders John Overdeck and David Siegel are worth an estimated $14 billion.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The new trading year is getting started, and investors might be looking to make this one either as strong as 2024 was or even stronger yet. To do this, it is always preferred to start on a strong note...

The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferie...

Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.

Investors love dividend stocks, especially the blue-chip variety, because they offer a significant income stream and have massive total return potential.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

It is no secret that the defensive names in the stock market today, the ones not known for their hot price action or wild return potential, have been the lackluster segment of the financial markets la...

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in t...

Dividend aristocrats, or companies that have paid and raised dividends for at least 25 years are some of the best value stocks to buy and hold. Many of them have solid balance sheets and a long record...

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning pos...